RedHill Biopharma (Israel) Valuation Overview

RDHL -- Israel Stock  

ILS 313.20  13.70  4.57%

RedHill Biopharma recent Real Value cannot be determined due to lack of data. The prevailing price of RedHill Biopharma is S313.2. Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Macroaxis determines value of RedHill Biopharma from analyzing the company fundamentals such as Price to Sales of 117.07times, Current Valuation of 672.94M and Return On Equity of (98.45)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Horizon     30 Days    Login   to change
RedHill Biopharma Ltd is currently regarded as top stock in price to sales category among related companies. It is rated below average in beta category among related companies . The ratio of Price to Sales to Beta for RedHill Biopharma Ltd is about  780.47 

Current Market Valuation

RedHill Biopharma Valuation Boundaries

Not valued
October 16, 2018
Market Value
Real Value
Target Odds
RedHill Biopharma is Unknown risk asset. Calculation of real value of RedHill Biopharma is based on 1 month time horizon. Increasing RedHill Biopharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Additionally take a look at Your Equity Center. Please also try CEO Directory module to screen ceos from public companies around the world.